Information, not a decision

Childhood cancers: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 13 Nov 2026

Open trials (2719)

NCT06590857	Phase 1/2	Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.	Recruiting
NCT05333458	Phase 2	Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial	Recruiting
NCT05372640	Phase 1	Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors	Recruiting
NCT06718244	Phase 2	Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1	Recruiting
NCT07502287	Phase 1/2	Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma	Recruiting
NCT07729397	Phase 1	Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma	Not yet recruiting
NCT07197554	Phase 1	A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies	Recruiting
NCT07223021	Phase 3	A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia	Recruiting
NCT07524530	Phase 2	Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers	Not yet recruiting
NCT06541262	Phase 1/2	Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors	Recruiting
NCT06303193	Phase 1/2	Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	Recruiting
NCT03258567	Phase 2	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas	Recruiting

2707 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

NCT06820957	22 Sept 2026	Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body	Stopped early
NCT06935409	7 Sept 2026	Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure	Completed
NCT04724369	30 Aug 2026	Open-Label Study of 18F-mFBG for Imaging Neuroblastoma	Completed

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 13 Nov 2026

https://frontlightresearch.com/en/doctor/childhood-cancers/tumor-board